Interní Med. 2003; 5(3): 32-34

Současné možnosti tokolytické léčby

MUDr. Ivana Špálová
Gynekologicko-porodnická klinika, 2. LF a FN v Motole, Univerzita Karlova v Praze

Keywords: tocolytics, premature delivery, beta-mimetics, calcium channel blockers, oxytocin antagonist.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Špálová I. Současné možnosti tokolytické léčby. Interní Med. 2003;5(3):32-34.

Předčasný porod je nejčastější přímou příčinou neonatálních úmrtí a závažným způsobem ovlivňuje krátkodobou i dlouhodobou morbiditu předčasně narozených (nedonošených) dětí. Počet předčasných porodů dosahuje 6-7 % a nadále stoupá, a to i přes zlepšující se diagnostické a terapeutické možnosti. V přehledu jsou uvedena tokolytika podle jednotlivých skupin, jejich účinnost, výhody, rizika užívání pro matku i pro plod a na závěr obecná pravidla pro jejich podávání.

Current possibilities of tocolytic therapy

Premature delivery is the main direct cause of neonatal death and it also has an important effect on both the short-term and long-term morbidity of these children. The number of preterm deliveries has reached 6-7 % and the incidence is increasing despite better diagnoses and therapy. The main groups of tocolytic drugs are listed in this review together with their efficacy, advantages, maternal and fetal risks and finally, guidelines for their administration.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beigelman A, Wiznitzer A, Shoham-Vardi I, Vardi H, Holtcberg G, Mazor M. Premature delivery in diabetes: etiology and risk factors. Harefuah 2000; 138: 919-923. Go to PubMed...
    2. Caughey AB, Parer JT. Tocolysis with beta-adrenergic receptor agonists. Semin Perinatol 2001; 25: 248-255. Go to original source... Go to PubMed...
    3. Coomarasamy A, Knox EM, Gee H, Khan KS. Oxytocin antagonists for tocolysis in preterm labour - a systematic review. Med Sci Monit 2002; 8: RA268-273.
    4. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999; 94: 869-877. Go to original source...
    5. Hack M, Merkatz IR. Preterm delivery and preterm birth - a dire legacy. New Engl J Med 1995; 333: 1772-1774. Go to original source... Go to PubMed...
    6. Joseph KS, Kramer MS, Marcoux S, Ohlsson A, Wen SW, Allen A, Platt R. Determinants of preterm birth rates in Canada from 1981 through 1983 nad from 1992 through 1994. New Engl J Med 1998; 339: 1434-1439. Go to original source... Go to PubMed...
    7. Katz VL, Farmer RM. Controversies in tocolytic therapy. Clin Obstet Gynecol 1999; 42: 802-819. Go to original source... Go to PubMed...
    8. King JF, Flenady VJ, Papatsonis DN, Dekker DA, Carbonne B. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst Rev 2003; CD002255. Go to original source...
    9. Macones GA, Marder SJ, Clothier B, Stamilio DM. The controversy surrounding indomethacin for tocolysis. Am J Obstet Gynecol 2001; 104: 264-272. Go to original source... Go to PubMed...
    10. Ramsey PS, Rouse DJ. Magnesium sulfate as a tocolytic agent. Semin Perinatol 2001; 25: 236-247. Go to original source... Go to PubMed...
    11. Sanchez-Ramos L, Kaunitz AM, Gaudier FL, Delke I. Efficacy of maintenance therapy after acute tokolysis: a meta-analysis. Am J Obstet Gynecol 1999; 181: 484-490. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.